Unravelling mechanisms of resistance to targeted drugs
17 Jul 2012
Unravelling mechanisms of resistance to targeted drugs
CORRECT study data prompts US FDA priority review
Anti-angiogenic trials; key highlights of the 14th WCGC
Epigenetics of cancer and changes in DNA modification in tumours
Perifosine disappoints in refractory mCRC
Screening and specialist nurses central to patient care
Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment
Adjuvant cetuximab disappoints again in mCRC
Young Voices United against CRC
Advances in radiotherapy for rectal cancer
Important to support young medical oncologists’ research
Role of family history and genetic testing in diagnosis